Alnylam Q4 2019 Earnings Report
Key Takeaways
Alnylam Pharmaceuticals reported strong ONPATTRO patient demand and excellent execution by commercial teams in Q4 2019. The company saw significant ONPATTRO new patient growth in the U.S. and EU, and strong initial demand in Japan. Alnylam also became a multi-product commercial company with the early U.S. approval of GIVLAARI in the fourth quarter.
Achieved global net product revenues for ONPATTRO of $55.8 million.
Over 750 patients worldwide receiving commercial ONPATTRO.
Observed strong initial demand for GIVLAARI in the U.S., with 13 Start Forms Received in First Six Weeks after FDA Approval.
Maintained strong balance sheet with Year-End Cash and Investments Balance of $1.55 Billion.
Alnylam
Alnylam
Alnylam Revenue by Segment
Forward Guidance
Alnylam provided full year 2020 financial guidance. ONPATTRO net product revenues are expected to be between $285 million and $315 million. Net revenues from collaborators are expected to be between $100 million - $150 million. GAAP R&D and SG&A expenses are expected to be between $1,180 million - $1,300 million. Non-GAAP R&D and SG&A expenses are expected to be between $1,025 million - $1,125 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income